Evidence map›Paper›PMID 41668133›Full record

ArticleMolecular cancer2026

CRISPR screen of human pancreatic cancer xenografts identifies a KLF5 proliferation vulnerability through epigenetic modifiers NCAPD2 and MTHFD1.

Masahiro Maeda, Kenna Sherman, Weiqiang Zhou, Jiaqi Cheng, Yuta Nihongaki, Adrian Idrizi, Rakel Tryggvadottir, Oscar Camacho, Xingbo Shang, Jimin Min and 6 more

Abstract read
In one paragraph

Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Masahiro Maeda *Center for Epigenetics, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Kenna Sherman *Center for Epigenetics, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Weiqiang Zhou *Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Jiaqi ChengDepartment of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Yuta NihongakiDepartment of Cell Biology and Center for Cell Dynamics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Adrian IdriziCenter for Epigenetics, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Rakel TryggvadottirCenter for Epigenetics, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Oscar CamachoCenter for Epigenetics, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Xingbo ShangDepartment of Biomedical Engineering and Yale Systems Biology Institute, Yale University, New Haven, CT, USA.
Jimin MinDepartment of Medicine, Laura and Isaac Perlmutter Cancer Center and New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA.
Michael A KoldobskiyCenter for Epigenetics, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA.
Anirban MaitraDepartment of Medicine, Laura and Isaac Perlmutter Cancer Center and New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USA.
Andre LevchenkoDepartment of Biomedical Engineering and Yale Systems Biology Institute, Yale University, New Haven, CT, USA.
Barbara S SlusherDepartments of Neurology, Pharmacology and Molecular Sciences, Psychiatry and Behavioral Sciences, Neuroscience, Oncology, and Medicine, Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hongkai JiDepartment of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Andrew P FeinbergCenter for Epigenetics, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Baltimore, MD, 21205, USA. afeinberg@jhu.edu.

Funding

MOLECULAR PATHOLOGY OF WILMS TUMOR RELATED GENES 11PR01CA054358 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDREW P. FEINBERG · 1991 to 2026
$5.5M
BWS and Embryonal Tumor Suppressor Genes on 11p15R37CA054358 · NCI · JOHNS HOPKINS UNIVERSITY · PI FEINBERG, ANDREW P. · 2001 to 2009
$4.0M
Predoctoral Training Program in Human GeneticsT32GM148383 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Kimberly F Doheny, ANDREW S MCCALLION · 2023 to 2026
$2.4M
Computational tools for regulome mapping using single-cell genomic dataR01HG010889 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI JI, HONGKAI · 2019 to 2022
$1.6M
Analytical Infrastructure for Multiple Sample Single Cell Genomic DataR01HG013409 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI Hongkai Ji · 2024 to 2026
$1.1M
NCI NIH HHS R01 CA054358NCI NIH HHS R37 CA054358NHGRI NIH HHS R01 HG010889NHGRI NIH HHS R01 HG013409NIGMS NIH HHS T32 GM148383NIGMS NIH HHS T32GM148383NIH HHS CA54358NIH HHS R01HG010889
6 · The paper itself

Abstract

One of the major conundrums of cancer research and treatment is that the metastases that lead to death in most patients do not appear to involve additional driver mutations. Previously, we reported widespread loss of heterochromatin with activation of pro-metastatic genes in the subset of cells of primary pancreatic tumors that gave rise to liver and lung metastases. Here we hypothesized that this change in chromatin could create unique vulnerabilities in distant metastases. Using a CRISPR screen of human patient-derived xenografts from metastases and primary tumors, we identified KLF5 as essential for metastatic cell proliferation but not primary tumor growth. Further, we found that KLF5 induced epigenetic modifier genes, including NCAPD2 and MTHFD1, which themselves facilitated expression of specific genes driving migration and epithelial-mesenchymal transition, including TGFBR2, VIM, EMP1, and ITGB1. Inhibition of expression of these modifier genes restored heterochromatin in the specific regions that distinguish the primary and metastatic tumors. We backed up this causal chain of evidence with rigorous additional knockdown experiments with the modifier genes, and single cell RNA and chromatin experiments, and we also replicated the main findings in a second set of paired primary and distant metastasis xenograft lines. Finally, KLF5 expression was strongly associated with patient survival and human PDAC cell plasticity in a dataset of 70 PDAC patients and KLF5 expression was increased in the majority of lung, liver and peritoneal metastases compared to the matched primary tumor, confirming its importance in PDAC metastasis and mortality. In summary, we have identified a cascade of epigenetic modulators, modifiers and mediators that maintains the widespread heterochromatin loss supporting metastatic cell proliferation in human pancreatic cancer (see Graphical Abstract).

Indexed as

Epigenesis, GeneticKruppel-Like Transcription FactorsMethylenetetrahydrofolate Dehydrogenase (NADP)Minor Histocompatibility AntigensPancreatic NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMiceKLF5 protein, humanKruppel-Like Transcription FactorsMethylenetetrahydrofolate Dehydrogenase (NADP)Minor Histocompatibility Antigens

Identifiers

PMID41668133
PMCPMC12998327

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.